Key Takeaways & Executive Findings
- •• MSC therapy significantly enhances liver function and mitigates liver inflammation after partial hepatectomy in fibrotic livers. • MSCs promote liver regeneration and alleviate liver fibrosis by activating Wnt/β-catenin signaling. • The combination of MSCs with hepatectomy offers a novel therapeutic approach for liver fibrotic diseases. • This study addresses the gap in MSC therapy for impaired liver regeneration in fibrosis context.
Abstract
Liver fibrosis is a critical stage in the progression of various chronic liver diseases to cirrhosis and liver cancer. Early inhibition of liver fibrosis is crucial for the treatment of liver disease. Hepatectomy, a common treatment for liver-related diseases, promotes liver regeneration. However, in the context of liver fibrosis, liver regeneration is hindered. Many studies have shown that mesenchymal stem cells (MSCs) can promote liver regeneration after partial hepatectomy (PH). However, there are few reports on the impact of MSC therapy on liver regeneration post-PH in the context of hepatic fibrosis. The objective of this study is to examine the impact of MSCs on liver regeneration following PH in the fibrotic liver and uncover the related molecular mechanisms. This study reveals that MSC therapy significantly enhances liver function and mitigates liver inflammation after PH in the context of hepatic fibrosis. MSCs also significantly promote liver regeneration and alleviate liver fibrosis. In addition, this study identifies the role of MSCs in promoting liver regeneration and alleviating liver fibrosis via the activation of Wnt/β-catenin signaling. The combination of MSCs with hepatectomy may offer a novel approach for the treatment of liver fibrotic diseases.
1. Introduction
As the largest and most important metabolic organ, the liver is crucial for substance synthesis and decomposition, energy metabolism, immune response, and detoxification. However, long-term chronic viral infection, alcohol, obesity, drugs, and toxins can cause irreversible liver damage. Chronic liver injury often leads to liver inflammation, fibrosis, cirrhosis, and even liver cancer [1]. Globally, approximately 1 to 1.2 million people die annually from liver fibrosis, cirrhosis, liver cancer, or their complications, significantly reducing life expectancy [2].
Liver fibrosis is characterized by excessive accumulation of extracellular matrix [3], and chronic liver injury poses a significant global health concern [4]. Hepatic stellate cells (HSCs) are crucial in the development and progression of hepatic fibrosis [5]. Unfortunately, effective treatments for liver fibrosis are limited to addressing the underlying cause or opting for liver transplantation [6].
One of its most remarkable features is the ability of the liver to regenerate from damage. In healthy individuals, the liver can compensate for the acute loss of up to 70%–75% of its total mass [7–9]. This regenerative ability makes living donor liver transplantation and partial hepatectomy (PH) possible [10,11]. Both procedures necessitate swift liver regeneration to maintain proper liver function and overall homeostasis.
Loading authentic research manuscript (Pages 1–5)...
Xuewei Li, Jinghui Feng, Haiqin Cheng, Ning Jin, Shanshan Jin, Zhizhen Liu, Jun Xu, Jun Xie (2026). Human umbilical cord mesenchymal stem cells enhance liver regeneration and decrease collagen content in fibrosis mice after partial hepatectomy by activating Wnt/β-catenin signaling. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2024207
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the main finding of this study?
The study demonstrates that human umbilical cord mesenchymal stem cells (MSCs) enhance liver regeneration and reduce collagen content in fibrotic mice after partial hepatectomy by activating Wnt/β-catenin signaling.
How do MSCs improve liver regeneration in fibrotic livers?
MSCs promote liver regeneration by activating Wnt/β-catenin signaling, which enhances hepatocyte proliferation and reduces fibrosis, thereby improving liver function.
What is the significance of this research for clinical treatment?
The combination of MSC therapy with hepatectomy may offer a novel approach for treating liver fibrotic diseases, potentially improving outcomes for patients with underlying fibrosis undergoing liver resection.
What are the key mechanisms involved in MSC-mediated liver regeneration?
The key mechanism involves activation of the Wnt/β-catenin signaling pathway, which is crucial for liver regeneration and repair, and also contributes to the antifibrotic effects of MSCs.
What is the context of this study in liver disease treatment?
Liver fibrosis is a critical stage in chronic liver disease progression, and effective treatments are limited. This study addresses the challenge of impaired liver regeneration in fibrotic livers post-hepatectomy, a common clinical scenario.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.